Mugimane Manjanatha received a Ph.D. degree in microbiology and genetics from Iowa State University, Ames, Iowa, USA. After an Oak Ridge Institute of Sciences and Engineering Postdoctoral Fellowship, he joined the Division of Genetic and Molecular Toxicology (DGMT) at the National Center for Toxicology Research (NCTR), the premier research center of the U.S. Food and Drug Administration. Dr. Manjanatha has been leading two laboratories involved in the transgenic mutational assay and the comet assay. Dr. Manjanatha is a recognized leader in the field of genetic toxicology especially in the use of transgenic animals for hazard identification, characterization, and risk assessment. His research interests also extend to modification of comet assay for the assessment of genotoxic and epigenetic mode of action of FDA regulated agents and gene expression profiling to determine mode of action as a tool for human risk assessment. Manjanatha serves on many FDA, International Life Science Institute (lLSI), Health and Environmental Sciences Institute (HESI), and Environmental Mutagenesis Society (EMS) committees that address the application of transgenic systems in hazard characterization and mode of action of FDA relevant agents. Dr. Manjanatha has more than 60 publications including book chapters and minireviews in peer-reviewed toxicology journals. He serves in the editorial boards of Molecular Biology Journal of International Scholarly Research and Toxicology Journal of the Scientific World. He also reviews articles for many toxicology journals including Environmental and Molecular Mutagenesis, Mutation Research, Carcinogenesis, and Toxicological Sciences. He has received several major awards and recently the FDA Commendable Service Award.
Biography Updated on 2 October 2013